Bank of New York Mellon
VRCA icon

Bank of New York Mellon’s Verrica Pharmaceuticals VRCA Stock Holding History

Bank of New York Mellon’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,361
Closed -$19.3K – 4274
2025
Q1 		$19.3K Hold
4,361
– – ﹤0.01% 4091
2024
Q4 		$30.5K Hold
4,361
– – ﹤0.01% 4096
2024
Q3 		$63.2K Sell
4,361
-1,507
-26% -$67.9K ﹤0.01% 4035
2024
Q2 		$428K Buy
5,868
+439
+8% +$33.7K ﹤0.01% 3662
2024
Q1 		$321K Sell
5,429
-144
-3% -$7.95K ﹤0.01% 3746
2023
Q4 		$408K Sell
5,573
-809
-13% -$33.2K ﹤0.01% 3668
2023
Q3 		$248K Sell
6,382
-22
-0.3% -$1.12K ﹤0.01% 3885
2023
Q2 		$369K Buy
6,404
+4,943
+338% +$300K ﹤0.01% 3747
2023
Q1 		$95K Buy
1,461
+311
+27% +$18.8K ﹤0.01% 4084
2022
Q4 		$31.6K Sell
1,150
-6
-0.5% -$160 ﹤0.01% 4298
2022
Q3 		$34K Hold
1,156
– – ﹤0.01% 4383
2022
Q2 		$22K Sell
1,156
-3,425
-75% -$172K ﹤0.01% 4484
2022
Q1 		$372K Sell
4,581
-12
-0.3% -$989 ﹤0.01% 3891
2021
Q4 		$420K Buy
4,593
+73
+2% +$8.27K ﹤0.01% 3909
2021
Q3 		$565K Buy
4,520
+300
+7% +$33.6K ﹤0.01% 3743
2021
Q2 		$476K Sell
4,220
-185
-4% -$22.4K ﹤0.01% 3794
2021
Q1 		$667K Sell
4,405
-674
-13% -$93.3K ﹤0.01% 3536
2020
Q4 		$584K Buy
5,079
+1,881
+59% +$173K ﹤0.01% 3541
2020
Q3 		$247K Sell
3,198
-85
-3% -$6.96K ﹤0.01% 3778
2020
Q2 		$362K Sell
3,283
-291
-8% -$33.7K ﹤0.01% 3626
2020
Q1 		$391K Hold
3,574
– – ﹤0.01% 3489
2019
Q4 		$568K Buy
3,574
+8
+0.2% +$1.18K ﹤0.01% 3531
2019
Q3 		$526K Sell
3,566
-195
-5% -$21.7K ﹤0.01% 3510
2019
Q2 		$437K Buy
3,761
+1,220
+48% +$114K ﹤0.01% 3667
2019
Q1 		$275K Buy
2,541
+875
+53% +$101K ﹤0.01% 3772
2018
Q4 		$136K Buy
1,666
+468
+39% +$56.8K ﹤0.01% 3920
2018
Q3 		$195K Buy
+1,198
New +$205K ﹤0.01% 3942

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of New York Mellon's VRCA Position: Q2 2025 in Review

Bank of New York Mellon sold out of Verrica Pharmaceuticals (VRCA) in Q2 2025, closing a stake of 4,361 shares — an estimated $19.3K sold.

Bank of New York Mellon first reported a position in VRCA in Q3 2018 and held it in 27 quarters. The position peaked at $667K in Q1 2021. 58 funds tracked by Wall St. Rank hold VRCA as of Q2 2025.

  • Bank of New York Mellon reported no remaining Verrica Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 4,361 Verrica Pharmaceuticals shares in Q2 2025, an estimated $19.3K.
  • Bank of New York Mellon first reported a position in Verrica Pharmaceuticals in Q3 2018 and held it in 27 quarters.
  • Bank of New York Mellon's Verrica Pharmaceuticals position peaked at $667K in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2025.

Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.